https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52602 Wed 18 Oct 2023 13:31:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52601 Wed 18 Oct 2023 13:03:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14945 Wed 11 Apr 2018 10:09:01 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29525 Wed 02 Mar 2022 14:29:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28795 15% reduction over their own baseline breathlessness intensity. Results: Eleven people had trial medication (eight males, median age 78 years (68 to 89); all had COPD; median Karnofsky 70 (50 to 80); six were on long-term home oxygen. Ten people completed day four. One person withdrew because of unsteadiness on day four. Five participants reached the 15% reduction, but only three went on to the extension study, all completing without toxicity. Conclusion: This study was safe, feasible and there appears to be a group who derive benefits comparable to titrated opioids. Given the widespread use of benzodiazepines for the symptomatic treatment of chronic refractory breathlessness and its poor evidence base, there is justification for a definitive phase III study.]]> Sat 24 Mar 2018 07:38:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54194 Mon 12 Feb 2024 14:43:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53098 Fri 17 Nov 2023 11:27:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49171 Fri 05 May 2023 15:37:31 AEST ]]>